Fundraising FoxLongeVC — 2025 Investments
2 investments dated 2025 · listed companies and verified rows first · show all
Trogenix develops precision gene therapies for cancer using its Odysseus platform and Synthetic Super-Enhancer (SSE) technology, engineered DNA elements activated only in diseased cell states to selectively target and kill tumour cells while activating the immune system.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesEdinburgh, GB
Ken Macnamarain
Co-investorsACADEMY INVESTORAIN VenturesCalculus Capital Ltd.IQ CapitalOld College Capital4BIO Capital
.jpeg){kind=logo}
Valink Therapeutics develops bispecific antibody-drug conjugates (ADCs) for therapeutic applications, combining high-throughput discovery, antibody engineering, and medicinal chemistry capabilities.
AI & Machine LearningBiotechHealthtechMedical DevicesBoston, US
Arne Scheu(Founder)inIrsyad Khairil(Founder)in
Co-investorsHoxton VenturesMetaplanetOxonian VenturesP53 InvestRV Invest GmbHSynBioVen+9 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.